This is a prospective cohort study that aims to determine the genetic risk of intrahepatic cholestasis of pregnancy (ICP) and identify if there are underlying gene mutations that lead to ICP, progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The primary objective of the study is to determine the prevalence, predictors, and obstetric outcomes of pathogenic cholestatic genetic variants among women diagnosed with ICP. 
   
We will determine the prevalence of known cholestatic genetic mutations as well as variants of unknown significance and correlate associations of genetic mutations with severity of disease, maternal characteristics, obstetric and neonatal outcomes. Data collection variables include basic demographics, bile acid level, symptomatology, liver test, prior liver disease, prior ICP, ursodiol use, gestational age at suspected diagnosis, gestational age at delivery, meconium, birth weight, Apgar score, and NICU admission. Pruritus symptoms 6 weeks postpartum will be assessed using an email survey.